Royalty Pharma PLC (RPRX) News

Royalty Pharma PLC (RPRX): $28.20

0.05 (-0.18%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

C

Add RPRX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#26 of 363

in industry

Filter RPRX News Items

RPRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RPRX News From Around the Web

Below are the latest news stories about ROYALTY PHARMA PLC that investors may wish to consider to help them evaluate RPRX as an investment opportunity.

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the la

Yahoo | November 27, 2023

Royalty Pharma plc (NASDAQ:RPRX) is a favorite amongst institutional investors who own 69%

Key Insights Given the large stake in the stock by institutions, Royalty Pharma's stock price might be vulnerable to...

Yahoo | November 26, 2023

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophreniaPhase 3 data expected in the second half of 2024 NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a collaboration to further accele

Yahoo | November 13, 2023

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

TEL AVIV, Israel & NEW YORK, November 13, 2023--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma plc (Nasdaq: RPRX), announced today a collaboration to further accelerate the clinical research program for Teva’s olanzapine LAI (TEV-‘749) by entering into a funding agreement of up to $125 million to offset program costs. Olanzapine LAI (TEV-‘749) is a once-monthly subcutaneous long-acting injection of the atypica

Yahoo | November 13, 2023

The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis

Decoding Royalty Pharma PLC (RPRX): A Strategic SWOT Insight

Yahoo | November 9, 2023

Royalty Pharma Reports Third Quarter 2023 Results

Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP) of $637 millionAnnounced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront paymentsRaising 2023 guidance: Adjusted Cash Receipts(1) (non-GAAP) expected to be $2,950 to $3,000 million NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2023 and raised full-year 2023 guidance fo

Yahoo | November 8, 2023

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfrontPTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 millionTransaction expected to enhance long-term Adjusted Cash Receipts growth (non-GAAP)Royalty Pharma to host conference call today, Thursday, October 19 at 9:00am EDT NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced tod

Yahoo | October 19, 2023

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on December 15, 2023, to shareholders of record at the close of business on November 17, 2023. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical

Yahoo | October 16, 2023

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/news-and-events/events to obtain conference

Yahoo | October 11, 2023

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology Officer, and a member of the Executive Leadership Team. During his tenur

Yahoo | September 21, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!